Additionally, the number of lymphocytes expressing IL-17 from patients with relapsing relapse-remitting MS (RRMS) was approximately 3-fold higher than in controls and remitting RRMS [54]. This evidence concerns the gene IL17A and relapsing-remitting multiple sclerosis.